Molecular Profile Detail

Profile Name MET amp
Gene Variant Detail

MET amp (no effect)

Relevant Treatment Approaches HGF Antibody MET Antibody MET Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET amp lung squamous cell carcinoma sensitive SCC244 Preclinical - Cell line xenograft Actionable In a preclinical study, SCC244 inhibited Met activity, downstream signaling, and cell proliferation in lung squamous cell carcinoma cells harboring MET amplification in culture, and inhibited tumor growth in cell line xenograft models (PMID: 29237805). 29237805
MET amp Advanced Solid Tumor sensitive MET Antibody ABT-700 Phase I Actionable In a Phase I trial, ABT-700 demonstrated safety and preliminary efficacy in patients with MET-amplified advanced solid tumors, including a patient with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2507)). detail...
MET amp non-small cell lung carcinoma predicted - resistant Osimertinib Clinical Study Actionable In a clinical case study, two patients with non-small cell lung cancer harboring EGFR T790M progressed after Tagrisso (osimertinib) treatment, and was found to have lost EGFR T790M and acquired MET amplification (PMID: 30268451). 30268451
MET amp non-small cell lung carcinoma predicted - resistant Osimertinib Clinical Study Actionable In a clinical case study, a patient with non-small cell lung cancer harboring EGFR amplification and EGFR T790M progressed after Tagrisso (osimertinib) treatment, and was found to have lost the EGFR mutations and acquired a MET amplification (PMID: 30268451). 30268451
MET amp lung cancer sensitive MET Inhibitor Glesatinib Preclinical - Cell culture Actionable In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth of MET-amplified lung cancer cells in culture (PMID: 28765324). 28765324
MET amp esophageal cancer sensitive MET Inhibitor AMG 337 Clinical Study Actionable In clinical case studies, patients with MET amplified esophageal cancer responded to AMG 337 therapy (PMID: 26432108). 26432108
MET amp lung cancer sensitive MET Inhibitor AMG 337 Preclinical - Cell culture Actionable In a preclinical study, AMG 337 inhibited growth of MET-amplified lung cancer cell lines in culture (PMID: 27196782). 27196782
MET amp Advanced Solid Tumor predicted - sensitive MET Inhibitor Capmatinib Phase I Actionable In a Phase I trial, INC280 displayed safety and preliminary efficacy in patients with MET dependent solid tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2520)). detail...
MET amp non-small cell lung carcinoma sensitive TAE226 Preclinical Actionable In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring MET amplification in culture (PMID: 26090892). 26090892
MET amp non-small cell lung carcinoma predicted - sensitive Alvespimycin Preclinical - Cell line xenograft Actionable In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Alvespimycin inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture and in cell line xenograft models (PMID: 26483207). 26483207
MET amp stomach cancer sensitive MET Inhibitor AMG 337 Preclinical - Cell line xenograft Actionable In a preclinical study, AMG 337 inhibited growth of gastric cancer cell lines in culture, and inhibited growth and induced regression of tumors in MET-amplified gastric cancer cell line xenograft models (PMID: 27196782). 27196782
MET amp lung cancer sensitive MET Inhibitor Golvatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of lung cancer cells in culture and tumor regression in cell line xenograft models (PMID: 19832844). 19832844
MET amp colorectal cancer resistant Cetuximab Clinical Study Actionable In a clinical study, MET amplification was associated with resistance to Erbitux (cetuximab) in 2 colorectal cancer patients, and in patient-derived xenograft (PDX) models (PMID: 23729478). 23729478
MET amp stomach carcinoma sensitive MET Inhibitor EMD 1214063 Preclinical - Cell line xenograft Actionable In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of gastric carcinoma harboring MET amplification (PMID: 23553846). 23553846
MET amp stomach cancer sensitive TAE226 Preclinical Actionable In a preclinical study, TAE226 treatment inhibited proliferation of gastric cancer cell lines harboring MET amplification in culture (PMID: 26090892). 26090892
MET amp non-small cell lung carcinoma sensitive MET Antibody MET Inhibitor KTN0073-IgG2 Preclinical - Cell culture Actionable In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited proliferation of a MET-amplified non-small cell lung cancer cell line in culture (PMID: 27550450). 27550450
MET amp stomach cancer sensitive MET Inhibitor TAS-115 Preclinical Actionable In a preclinical study, MET amplified gastric cancer cell lines were sensitive to TAS-115, resulting in suppression of cell proliferation in culture (PMID: 24140932). 24140932
MET amp stomach cancer sensitive MET Antibody MET Inhibitor KTN0073-IgG2 Preclinical - Cell line xenograft Actionable In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited growth of a MET-amplified gastric cancer cell line in culture and in xenograft models (PMID: 27550450). 27550450
MET amp non-small cell lung carcinoma sensitive MET Inhibitor EMD 1214063 Preclinical - Cell line xenograft Actionable In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of non-small cell lung carcinoma harboring MET amplification (PMID: 23553846). 23553846
MET amp non-small cell lung carcinoma sensitive BEZ235 Preclinical Actionable In a preclinical study, BEZ235 suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055). 24939055
MET amp Advanced Solid Tumor decreased response MET Inhibitor AMG 337 Clinical Study Actionable In a retrospective study, advanced solid tumor patients harboring MET amplification only achieved stable disease in 29% (2/7) of the population, while MET-nonamplified patients achieved partial response in 10% (14/134) and stable disease in 36% (48/134) of the population, when treated with Met inhibitors including AMG 337 and EMD 1204831 (PMID: 25326232). 25326232
MET amp Advanced Solid Tumor sensitive MET Antibody SYM015 Preclinical - Pdx & cell culture Actionable In a preclinical study, Sym015 inhibited growth of cancer cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified patient-derived xenograft (PDX) models (Cancer Res July 15 2016 (76) (14 Supplement) 1219). detail...
MET amp non-small cell lung carcinoma sensitive Selumetinib + BEZ235 Preclinical - Cell line xenograft Actionable In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically inhibited proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring MET amplification in culture and in cell line xenograft models (PMID: 24939055). 24939055
MET amp Advanced Solid Tumor not applicable N/A Clinical Study Emerging In a retrospective study, advanced solid tumor patients harboring MET amplification demonstrated worse overall survival (7.23 months) comparing to patients without MET amplification (8.62 months) (PMID: 25326232), suggesting that this may serve as a future prognostic biomarker. 25326232
MET amp liver cancer sensitive MET Inhibitor Crizotinib Preclinical - Pdx Actionable In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified liver cancer (PMID: 26483207). 26483207
MET amp stomach cancer sensitive M-COPA Preclinical - Cell line xenograft Actionable In a preclinical study, M-COPA reduced Met cell surface expression and downstream signaling and decreased growth of MET-amplified gastric cancer cell lines in culture, and demonstrated antitumor activity in MET-amplified gastric cancer cell line xenograft models (PMID: 27197184). 27197184
MET amp Advanced Solid Tumor decreased response MET Inhibitor EMD 1204831 Clinical Study Actionable In a retrospective study, advanced solid tumor patients harboring MET amplification only achieved stable disease in 29% (2/7) of the population, while MET-nonamplified patients achieved partial response in 10% (14/134) and stable disease in 36% (48/134) of the population, when treated with Met inhibitors including AMG 337 and EMD 1204831 (PMID: 25326232). 25326232
MET amp stomach cancer sensitive SCC244 Preclinical - Cell line xenograft Actionable In a preclinical study, SCC244 inhibited Met activity, downstream signaling, and cell proliferation in gastric cancer cells harboring MET amplification in culture, and inhibited tumor growth in cell line xenograft models (PMID: 29237805). 29237805
MET amp lung cancer sensitive MET Inhibitor SAR125844 Preclinical - Cell culture Actionable In a preclinical study, SAR125844 inhibited Met signaling, leading to growth inhibition of MET amplified lung cancer cells in culture (PMID: 25504634). 25504634
MET amp non-small cell lung carcinoma predicted - sensitive PP-121 Preclinical - Cell culture Actionable In a preclinical study, the multitarget kinase inhibitor PP-121 inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207). 26483207
MET amp stomach cancer no benefit FF-284 Preclinical - Cell line xenograft Actionable In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of MET amplified gastric cancer (PMID: 26438159). 26438159
MET amp hepatocellular carcinoma sensitive MET Inhibitor AMG 337 Preclinical - Pdx & cell culture Actionable In a preclinical study, AMG 337 inhibited Met phosphorylation and growth of hepatocellular carcinoma (HCC) cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified HCC patient-derived xenograft models (PMID: 27196749). 27196749
MET amp stomach cancer sensitive MET Inhibitor SAR125844 Preclinical - Cell line xenograft Actionable In a preclinical study, SAR125844 inhibited Met signaling leading to growth inhibition of MET amplified gastric cancer cell lines in culture and in xenograft models (PMID: 25504634). 25504634
MET amp non-small cell lung carcinoma sensitive MET Inhibitor Capmatinib Phase I Actionable In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 63% (5/8) of MET amplified non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)). detail...
MET amp non-small cell lung carcinoma sensitive Selumetinib Preclinical Actionable In a preclinical study, Selumetinib (AZD6244) suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055). 24939055
MET amp stomach cancer sensitive MET Inhibitor SGX523 Preclinical - Cell line xenograft Actionable In a preclinical study, SGX523 inhibited Met signaling and proliferation of MET amplified gastric cancer cells in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 19934279). 19934279
MET amp non-small cell lung carcinoma sensitive SCC244 Preclinical - Pdx Actionable In a preclinical study, non-small cell lung carcinoma patient-derived xenograft models harboring MET amplification were sensitive to SCC244, demonstrating inhibition of tumor growth and stable disease (PMID: 29237805). 29237805
MET amp stomach cancer sensitive MET Antibody Telisotuzumab vedotin Preclinical - Cell line xenograft Actionable In a preclinical study, ABBV-399 inhibited growth of MET-amplified gastric cancer cell in culture, and induced tumor regression in a MET-amplified gastric cancer cell line xenograft model (PMID: 27573171). 27573171
MET amp Advanced Solid Tumor sensitive MET Inhibitor Tepotinib Phase I Actionable In a Phase I study, Tepotinib (MSC2156119J) demonstrated safety and preliminary efficacy in advanced solid tumor patients with MET amplification (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2591). detail...
MET amp Advanced Solid Tumor predicted - sensitive MET Inhibitor SAR125844 Phase I Actionable In a Phase I trial, SAR125844 treatment in advanced solid tumor patients harboring a MET amplification was well-tolerated and resulted in a partial response in 17% (5/29) of patients, including patients with non-small cell lung carcinoma, and stable disease in 59% (17/29) of patients (PMID: 29145039; NCT01391533). detail... 29145039
MET amp non-small cell lung carcinoma sensitive MET Inhibitor Crizotinib Preclinical - Pdx Actionable In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified non-small cell lung cancer (PMID: 26483207). 26483207
MET amp non-small cell lung carcinoma sensitive MET Inhibitor Crizotinib Guideline Actionable Xalkori (crizotinib) is included in guidelines for non-small cell lung cancer patients with high level MET amplification (NCCN.org). detail...
MET amp non-small cell lung carcinoma predicted - sensitive Dasatinib Preclinical - Cell culture Actionable In a preclinical study, the multitarget kinase inhibitor Sprycel (dasatinib) inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207). 26483207
MET amp colorectal cancer sensitive MET Inhibitor JNJ 38877605 Preclinical - Pdx Actionable In a preclinical study, JNJ-38877605 inhibited tumor growth in colorectal cancer patient-derived xenograft models with MET amplification (PMID: 23729478). 23729478
MET amp Advanced Solid Tumor sensitive MET Antibody MET Inhibitor Emibetuzumab Preclinical Actionable In a preclinical study, Emibetuzumab (LY2875358) treatment inhibited MET activation and proliferation of tumor cells with MET amplification in culture, and inhibited growth in MET-amplified tumor xenograft models (PMID: 25231402). 25231402
MET amp stomach cancer sensitive MET Inhibitor Golvatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of gastric cancer cell lines in culture and in cell line xenograft models (PMID: 19832844). 19832844
MET amp papillary renal cell carcinoma sensitive MET Inhibitor Savolitinib Preclinical - Pdx Actionable In a preclinical study, Savolitinib (AZD6094) demonstrated antitumor activity in patient-derived papillary renal cell carcinoma xenograft models harboring MET amplification (PMID: 25779944). 25779944
MET amp papillary renal cell carcinoma sensitive MET Inhibitor Savolitinib Phase II Actionable In a Phase II trial, treatment with Savolitinib (AZD6094) resulted in an overall response rate (ORR) of 18% (8/44, all partial responses) in the subgroup of patients with MET-driven papillary renal cell carcinoma (PRCC), which included patients with MET amplification, compared to an ORR of 0% (0/46) in patients with MET-independent PRCC (PMID: 28644771; NCT02127710). 28644771
MET amp non-small cell lung carcinoma sensitive MET Inhibitor SGX523 Preclinical - Cell culture Actionable In a preclinical study, SGX523 inhibited survival of MET-amplified non-small cell lung cancer cells in culture (PMID: 26483207). 26483207
MET amp stomach cancer sensitive MET Inhibitor Glesatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Glesatinib (MGCD265) treatment resulted in tumor regression in MET-amplified gastric cancer cell line xenograft models (PMID: 28765324). 28765324
MET amp non-small cell lung carcinoma predicted - sensitive MET Inhibitor Merestinib Preclinical - Pdx Actionable In a preclinical study, Merestinib (LY2801653) treatment resulted in growth inhibition in patient-derived xenograft (PDX) models of MET-amplified non-small cell lung carcinoma that were resistant to Egfr inhibitors (Cancer Res 2010;70(8 Suppl):Abstract nr 3611). detail...
MET amp stomach cancer sensitive MET Antibody ARGX-111 Phase I Actionable In a Phase I trial, a gastric cancer patient harboring MET amplification was sensitive to treatment with ARGX-111, demonstrating stable disease, a metabolic response, and a decrease in circulating tumor cells (Journal of Clinical Oncology 33, no. 15_suppl (May 2015) 2580-2580). detail...
MET amp esophagus adenocarcinoma sensitive MET Inhibitor AMG 337 Clinical Study Actionable In a clinical case study, a patient with MET amplified esophageal adenocarcinoma had a partial response to AMG 337 therapy after 2 months of treatment (PMID: 26432108). 26432108
MET amp non-small cell lung carcinoma predicted - sensitive Ganetespib Preclinical - Cell culture Actionable In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Ganetespib inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207). 26483207
Clinical Trial Phase Therapies Title Recruitment Status
NCT02465060 Phase II Dabrafenib Trametinib Crizotinib Sunitinib Sapanisertib Nivolumab AZD4547 Dasatinib Binimetinib Adavosertib Osimertinib Trastuzumab Palbociclib Afatinib Capivasertib Defactinib GSK2636771 Vismodegib trastuzumab emtansine Larotrectinib Pertuzumab Taselisib Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting
NCT00697632 Phase I Glesatinib Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies Completed
NCT03592641 Phase II Savolitinib Volitinib in Treating Participants With MET Amplified Metastatic or Unresectable Colorectal Cancer Not yet recruiting
NCT00585195 Phase I Crizotinib + Itraconazole Crizotinib + Rifampin A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer Recruiting
NCT02016534 Phase II AMG 337 Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors Terminated
NCT02580708 Phase Ib/II Trametinib Rociletinib A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Terminated
NCT02468661 Phase Ib/II Capmatinib Erlotinib Cisplatin + Pemetrexed Carboplatin + Pemetrexed A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification Recruiting
NCT03040973 FDA approved Capmatinib Roll-over Study for Patients With cMET-dependent Malignancies Who Previously Completed a Novartis Capmatinib Study Recruiting
NCT03175224 Phase I CBT-101 CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation Recruiting
NCT01391533 Phase I SAR125844 Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors Completed
NCT03755102 Phase I Dacomitinib A Study of Dacomitinib in Patients With Metastatic EGFR Mutant Lung Cancer Previously Treated With Osimertinib Recruiting
NCT02132598 Phase II Cabozantinib Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases Recruiting
NCT02925104 Phase I Capmatinib A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. Completed
NCT03468985 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Nivolumab Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer Suspended
NCT02648724 Phase Ib/II SYM015 Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies Recruiting
NCT03598244 Phase I Savolitinib Volitinib in Treating Participants With Recurrent or Refractory Primary CNS Tumors Suspended
NCT03260491 Phase I U3-1402 U3-1402 in Metastatic or Unresectable EGFR-mutant Non-Small Cell Lung Cancer Recruiting
NCT03255083 Phase I DS-1205c + Osimertinib DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Recruiting
NCT03778229 Phase II Osimertinib + Savolitinib Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH) Recruiting
NCT02435121 Phase II SAR125844 A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification Completed